Table 1.
Main characteristics of 31 patients with primary FSGS at disease onset and at the time of the first RTX administration
| Characteristics | Disease onset | First RTX administration |
|---|---|---|
| Age (yr) | 37 (26–42) | 40 (32–50) |
| Male sex | 18 (58) | |
| Weight (kg) | 69.50 (59.50–78.25) | 66.00 (59.00–75.00) |
| Systolic blood pressure (mm Hg) | 125 (120–150) | 120 (110–130) |
| Diastolic blood pressure (mm Hg) | 85 (74–90) | 78 (70–85) |
| Serum creatinine (mg/dl) | 1.07 (0.70–1.30) | 1.17 (0.83–1.62) |
| eGFRa (ml/min) | 80.30 (62.18–120.75) | 72.00 (49.80–100.04) |
| Proteinuria (g/24 h) | 7.20 (4.70–10.48) | 5.20 (3.30–8.81) |
| Serum total protein (g/dl) | 4.50 (4.00–5.40) | 4.95 (4.60–5.85) |
| Serum total albumin (g/dl) | 2.23 (1.89–3.00) | 2.78 (2.17–3.60) |
| Total cholesterol (mg/dl) | 317.00 (259.00–383.00) | 237.00 (200.00–323.00) |
| Triglycerides (mg/dl) | 158.50 (110.25–197.75) | 169.00 (94.50–215.00) |
| Relapse rate before RTX (n/100 patient-yr) | 47 | |
| Schemes of RTX dosing | ||
| 2 × 1000 mg 2 wk apart | 10 (32) | |
| 4 × 375 mg/m2 weekly | 8 (26) | |
| 2 × 500 mg 2 wk apart | 6 (19) | |
| 1 × 375 mg/m2 | 4 (13) | |
| 1 × 1000 mg | 2 (6) | |
| 1 × 500 mg | 1 (3) | |
| FSGS histologic variants | ||
| NOS | 22 (73) | |
| Tip | 3 (10) | |
| Collapsing | 3 (10) | |
| Cellular | 2 (7) | |
eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerular sclerosis; MDRD, Modification of Diet in Renal Disease; NOS, not otherwise specified; RTX, rituximab.
a
Using the MDRD equation.
Results are expressed as n (%) for categorical variables and median (interquartile range) for continuous variables.